Gaedigk A - Search Results

1

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.

Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, Müller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Crews KR, et al. Among authors: gaedigk a. Clin Pharmacol Ther. 2021 Oct;110(4):888-896. doi: 10.1002/cpt.2149. Epub 2021 Feb 9. Clin Pharmacol Ther. 2021. PMID: 33387367 Free PMC article. Review.

2

Epitope mapping studies with human anti-cytochrome P450 3A antibodies.

Leeder JS, Gaedigk A, Lu X, Cook VA. Leeder JS, et al. Among authors: gaedigk a. Mol Pharmacol. 1996 Feb;49(2):234-43. Mol Pharmacol. 1996. PMID: 8632755

3

Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase.

Gaedigk A, Leeder JS, Grant DM. Gaedigk A, et al. DNA Cell Biol. 1997 Nov;16(11):1257-66. doi: 10.1089/dna.1997.16.1257. DNA Cell Biol. 1997. PMID: 9406998

4

Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions.

Leeder JS, Lu X, Timsit Y, Gaedigk A. Leeder JS, et al. Among authors: gaedigk a. Pharmacogenetics. 1998 Jun;8(3):211-25. doi: 10.1097/00008571-199806000-00004. Pharmacogenetics. 1998. PMID: 9682267

5

NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.

Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. Gaedigk A, et al. Pharmacogenetics. 1998 Aug;8(4):305-13. doi: 10.1097/00008571-199808000-00004. Pharmacogenetics. 1998. PMID: 9731717

6

Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.

Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS Jr. Kashuba AD, et al. Among authors: gaedigk a. Pharmacogenetics. 1998 Oct;8(5):403-10. doi: 10.1097/00008571-199810000-00005. Pharmacogenetics. 1998. PMID: 9825832

7

High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data.

Bradford LD, Gaedigk A, Leeder JS. Bradford LD, et al. Among authors: gaedigk a. Psychopharmacol Bull. 1998;34(4):797-804. Psychopharmacol Bull. 1998. PMID: 10513455 Review.

8

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.

Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr. Streetman DS, et al. Among authors: gaedigk a. Clin Pharmacol Ther. 1999 Nov;66(5):535-41. doi: 10.1016/S0009-9236(99)70018-4. Clin Pharmacol Ther. 1999. PMID: 10579482 Clinical Trial.

9

Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.

Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Gaedigk A, et al. Pharmacogenetics. 1999 Dec;9(6):669-82. doi: 10.1097/01213011-199912000-00002. Pharmacogenetics. 1999. PMID: 10634130

10

Interethnic differences of drug-metabolizing enzymes.

Gaedigk A. Gaedigk A. Int J Clin Pharmacol Ther. 2000 Feb;38(2):61-8. doi: 10.5414/cpp38061. Int J Clin Pharmacol Ther. 2000. PMID: 10706192 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page